Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Johanna Mercier
Pharma
FDA approves Gilead's Livdelzi for primary biliary cholangitis
The FDA has approved Gilead's liver disease drug Livdelzi, which was acquired in a $4.3 billion buyout of CymaBay Therapeutics six months ago.
Kevin Dunleavy
Aug 14, 2024 3:29pm
Gilead CEO Daniel O'Day scores $19M in 2021 compensation
Mar 25, 2022 9:32am
Gilead reports $5.6B in '21 Veklury sales, projects $2B in '22
Feb 2, 2022 7:05am
Veklury sales boost Gilead’s top line to $7.4B
Oct 29, 2021 7:04am
Pharma's quarterly earnings shows lots of growth despite COVID
Aug 11, 2021 11:30am
Gilead's revenues fluctuate with the pandemic
Jul 30, 2021 1:00am
